Apollo Hospitals Enterprise (APOLLOHOSP) — Financial Results

Investor Takeaways

Transcript of Q1 FY27 earnings call made available to investors

Revenue reached ₹6,605.5 Cr in Q4FY26 with 15.31% OPM

Annualized revenue growth of 12.8% observed across last four quarters

⚠️ No financial results or guidance disclosed in this filing

Overall Tone: Neutral based on the numbers only.

Key Financial Highlights

Metric	Value	YoY Change
Revenue	₹6,605.5 Cr	12.8% (annualized from sequential growth)
Net Profit	₹551.3 Cr	11.6% (from Q3FY26)
EBITDA	Not available	Not available
EPS	[amount context mismatch]	22.3% (from Q3FY26)
OPM	15.31%	0.41 percentage point increase (from Q3FY26)

What Changed

The filing confirms the availability of the transcript for the August 13, 2026 presentation on unaudited financial results for the quarter ended June 30, 2026. However, no financial figures or operational commentary are included in this announcement. The document only provides a link to the transcript for investor access.

Analysis of the quarterly trend reveals consistent performance across the last four quarters. Revenue grew from ₹5,842.1 Cr in Q1FY26 to ₹6,605.5 Cr in Q4FY26, reflecting a 12.8% annualized growth rate. Net profit increased from ₹441 Cr to ₹551.3 Cr over the same period, with a corresponding rise in OPM from 14.58% to 15.31%. EPS also showed growth from [amount not verified]to ₹36.82, indicating improved profitability per share. These metrics suggest stable operational expansion without any disclosed financial guidance or forward-looking statements in this particular filing.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Apollo Hospitals Enterprise Limited	64.49	21.94%	20.5%	1,16,213.95
Sun Pharmaceutical Industries Limited	41.28	15.11%	20.34%	4,50,643.09
Divi's Laboratories Limited	72.41	16.56%	22.09%	1,79,470.03
Torrent Pharmaceuticals Limited	80.06	N/A	N/A	1,49,108.91

Apollo Hospitals trades at a premium valuation compared to Sun Pharmaceutical but shows stronger profitability metrics with higher ROE and ROCE. Its debt-equity ratio of 0.64 is moderate compared to peers, though higher than Sun Pharmaceutical’s 0.03.

Risks & Concerns

No specific risks identified in this filing

No forward-looking guidance or commentary provided

Quarterly Trend

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	OPM%
Q4FY26	6,605.5	551.3	15.31
Q3FY26	6,477.4	516.3	14.9
Q2FY26	6,303.5	494	14.93
Q1FY26	5,842.1	441	14.58

📄 View Original Announcement (PDF)

📊 Stock Analysis — APOLLOHOSP ✨ Ask AI About This

About Apollo Hospitals Enterprise Limited (APOLLOHOSP)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹1,27,397.52 Cr P/E: 61.0 ROE: 22.9% ROCE: 22.1% Div Yield: 0.23%

View full APOLLOHOSP stock details →

📡 Get AI alerts when APOLLOHOSP files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track APOLLOHOSP — Free

💡 Ask AI about this filing

"When will Q1 FY27 financial results be published?" "What revenue growth did the company achieve YoY?" "How does management view profitability trends?"

Ask AI Free →

📊 More APOLLOHOSP filings

See all APOLLOHOSP filings →

🔥 Also filed on 19 August 2026

GOCOLORS Go Fashion (India) Limited Annual Report OIL Oil India Limited Corporate Action GLAXO GlaxoSmithKline Pharmaceuticals Limited Financial Results TIL TIL Limited Financial Results SETUINFRA Setubandhan Infrastructure Limited Financial Results ASALCBR Associated Alcohols & Breweries Ltd. Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when APOLLOHOSP files new disclosures

Track APOLLOHOSP filings, board meetings, and corporate actions. Free email alerts at 5 PM.